Health & beauty
Breye Therapeutics
Breye Therapeutics
Oral medicines for early-stage retinal diseases, starting with diabetic retinopathy.
Denmark. Founded in 2019, led by CEO Ulrik Mouritzen.
Announced a 67.5 million euro Series A led by Mission BioCapital and Novo Holdings on 2 October 2026.
Written by our editors from public sources, linked in our story. Not a paid placement. Founders can request a correction.